跳至主要内容
临床试验/NCT05973656
NCT05973656招募中不适用

Dissecting the Role of Acetaldehyde in Oral Carcinogenesis

Masonic Cancer Center, University of Minnesota1 个研究点 分布在 1 个国家目标入组 170 人开始时间: 2022年7月8日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
招募中
入组人数
170
试验地点
1
主要终点
Determine the acetaldehyde exposure to the oral cavity by comparing saliva levels before and after alcohol dose

研究概览

简要总结

This is a minimal risk intervention study where healthy volunteers and individuals with Fanconi anemia will consume a single dose of alcohol and provide primarily non-invasive biological samples at various time points. Biospecimens to be collected include saliva, oral cells collected via mouthwash and cheek brush, and urine. The collection of two blood samples (5 mL each) will be optional and banked for future use.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 45 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • 21-45 years of age for alcohol drinkers
  • Occasionally consume alcohol
  • At least 1 drink per month for healthy volunteers
  • At least 1 drink in the last 3 months for Fanconi anemia patients
  • Meets one of the three criteria
  • Healthy volunteer - ALDH2*1/1* homozygotes-not of Eastern Asian decent;
  • Healthy volunteer - ALDH2*1/2* heterozygotes-of Eastern Asian decent and experience flushing when drinking
  • Individual's with Fanconi anemia (FA).
  • 18-45 years of age for non-drinkers
  • Never consume alcohol/not had alcohol in the last 6 months
  • Healthy volunteers.
  • Non-smoker (smoked < 100 cigarettes in a lifetime)

排除标准

  • Pregnant or nursing
  • Taking any medication or drug that might affect alcohol use and absorption or that might be affected by alcohol consumption
  • Healthy volunteers who have taken any antibiotics in the last 3 months
  • Currently consuming more than 21 drinks per week
  • Have any history of alcohol or drug related problems
  • Current or former tobacco/nicotine product(s) user
  • Any regular use of tobacco/nicotine products or marijuana in the last year (cigarettes, e-cigarettes, cigars, pipes, smokeless tobacco)
  • "Trying" or limited use of any nicotine products or marijuana in the last 1 month
  • Active infection (influenza, cold, COVID, respiratory / sinus infection) - admission in the study will be delayed pending improved health
  • Non-FA volunteers who have an unstable medical condition or condition that could be affected by alcohol consumption (insulin-dependent diabetes, ulcers, heart issues)
  • Experience severe adverse events (nausea, blacking out) when consuming even low doses of alcohol

研究组 & 干预措施

Group I (alcohol consumption)

Experimental

Participants who consume alcohol receive a standard drink or an alcohol dose that will result in a 0.03% BAC PO on study. Participants also undergo collection of saliva and breathalyzer testing throughout the trial.

干预措施: Alcohol (Drug)

Group I (alcohol consumption)

Experimental

Participants who consume alcohol receive a standard drink or an alcohol dose that will result in a 0.03% BAC PO on study. Participants also undergo collection of saliva and breathalyzer testing throughout the trial.

干预措施: Biospecimen Collection (Procedure)

Group I (alcohol consumption)

Experimental

Participants who consume alcohol receive a standard drink or an alcohol dose that will result in a 0.03% BAC PO on study. Participants also undergo collection of saliva and breathalyzer testing throughout the trial.

干预措施: Breath Test (Procedure)

Group II (biospecimen collection)

Active Comparator

Participants who do not drink alcohol undergo collection of saliva, mouthwash, and cheek brush samples throughout the trial.

干预措施: Biospecimen Collection (Procedure)

Group II (biospecimen collection)

Active Comparator

Participants who do not drink alcohol undergo collection of saliva, mouthwash, and cheek brush samples throughout the trial.

干预措施: Breath Test (Procedure)

结局指标

主要结局

Determine the acetaldehyde exposure to the oral cavity by comparing saliva levels before and after alcohol dose

时间窗: Prior to alcohol dose, and 30 minutes, 1 hour, 2 hours, 4 hours, and 6 hours post alcohol dose

Identify and quantify DNA adducts in the oral cells (mouthwash and cheek brush samples).

次要结局

  • Urine will be analyzed to confirm non-smoking status(Up to 6 hours after alcohol exposure)
  • Urine will be analyzed to confirm non-smoking status(Prior to alcohol exposure)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

撤回
1 期
Evaluation of Ingenol Mebutate for Actinic Cheilitis TreatmentActinic Cheilitis
NCT03452566Instituto Nacional de Cancer, Brazil
已完成
不适用
The Effect of N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary SarcoidosisPulmonary Sarcoidosis
NCT01587001National Jewish Health17
已完成
2 期
Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation TherapyMucositisOral ComplicationsRecurrent Adenoid Cystic Carcinoma of the Oral CavityRecurrent Basal Cell Carcinoma of the LipRecurrent Lymphoepithelioma of the NasopharynxRecurrent Lymphoepithelioma of the OropharynxRecurrent Mucoepidermoid Carcinoma of the Oral CavityRecurrent Salivary Gland CancerRecurrent Squamous Cell Carcinoma of the LarynxRecurrent Squamous Cell Carcinoma of the Lip and Oral CavityRecurrent Squamous Cell Carcinoma of the NasopharynxRecurrent Squamous Cell Carcinoma of the OropharynxRecurrent Verrucous Carcinoma of the LarynxRecurrent Verrucous Carcinoma of the Oral CavityStage I Adenoid Cystic Carcinoma of the Oral CavityStage I Basal Cell Carcinoma of the LipStage I Lymphoepithelioma of the NasopharynxStage I Lymphoepithelioma of the OropharynxStage I Mucoepidermoid Carcinoma of the Oral CavityStage I Salivary Gland CancerStage I Squamous Cell Carcinoma of the LarynxStage I Squamous Cell Carcinoma of the Lip and Oral CavityStage I Squamous Cell Carcinoma of the NasopharynxStage I Squamous Cell Carcinoma of the OropharynxStage I Verrucous Carcinoma of the LarynxStage I Verrucous Carcinoma of the Oral CavityStage II Adenoid Cystic Carcinoma of the Oral CavityStage II Basal Cell Carcinoma of the LipStage II Lymphoepithelioma of the NasopharynxStage II Lymphoepithelioma of the OropharynxStage II Mucoepidermoid Carcinoma of the Oral CavityStage II Salivary Gland CancerStage II Squamous Cell Carcinoma of the LarynxStage II Squamous Cell Carcinoma of the Lip and Oral CavityStage II Squamous Cell Carcinoma of the NasopharynxStage II Squamous Cell Carcinoma of the OropharynxStage II Verrucous Carcinoma of the LarynxStage II Verrucous Carcinoma of the Oral CavityStage III Adenoid Cystic Carcinoma of the Oral CavityStage III Basal Cell Carcinoma of the LipStage III Lymphoepithelioma of the NasopharynxStage III Lymphoepithelioma of the OropharynxStage III Mucoepidermoid Carcinoma of the Oral CavityStage III Salivary Gland CancerStage III Squamous Cell Carcinoma of the LarynxStage III Squamous Cell Carcinoma of the Lip and Oral CavityStage III Squamous Cell Carcinoma of the NasopharynxStage III Squamous Cell Carcinoma of the OropharynxStage III Verrucous Carcinoma of the LarynxStage III Verrucous Carcinoma of the Oral CavityStage IV Lymphoepithelioma of the NasopharynxStage IV Squamous Cell Carcinoma of the NasopharynxStage IVA Adenoid Cystic Carcinoma of the Oral CavityStage IVA Basal Cell Carcinoma of the LipStage IVA Lymphoepithelioma of the OropharynxStage IVA Mucoepidermoid Carcinoma of the Oral CavityStage IVA Salivary Gland CancerStage IVA Squamous Cell Carcinoma of the LarynxStage IVA Squamous Cell Carcinoma of the Lip and Oral CavityStage IVA Squamous Cell Carcinoma of the OropharynxStage IVA Verrucous Carcinoma of the LarynxStage IVA Verrucous Carcinoma of the Oral CavityStage IVB Adenoid Cystic Carcinoma of the Oral CavityStage IVB Basal Cell Carcinoma of the LipStage IVB Lymphoepithelioma of the OropharynxStage IVB Mucoepidermoid Carcinoma of the Oral CavityStage IVB Salivary Gland CancerStage IVB Squamous Cell Carcinoma of the LarynxStage IVB Squamous Cell Carcinoma of the Lip and Oral CavityStage IVB Squamous Cell Carcinoma of the OropharynxStage IVB Verrucous Carcinoma of the LarynxStage IVB Verrucous Carcinoma of the Oral CavityStage IVC Adenoid Cystic Carcinoma of the Oral CavityStage IVC Basal Cell Carcinoma of the LipStage IVC Lymphoepithelioma of the OropharynxStage IVC Mucoepidermoid Carcinoma of the Oral CavityStage IVC Salivary Gland CancerStage IVC Squamous Cell Carcinoma of the LarynxStage IVC Squamous Cell Carcinoma of the Lip and Oral CavityStage IVC Squamous Cell Carcinoma of the OropharynxStage IVC Verrucous Carcinoma of the LarynxStage IVC Verrucous Carcinoma of the Oral CavityTongue Cancer
NCT02123511Mayo Clinic34
已完成
不适用
Acidophilus for the Treatment and Prevention of Oral Candidiasis in Patients Undergoing Radiation TherapyOral Candidiasis
NCT00768794Summa Health System5
已完成
不适用
The Use of Candy and Honey in Decreasing Salivary Gland Damage Following Radioiodine Therapy for Thyroid CancerThyroid Cancer
NCT01833650Cyprus University of Technology120